Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listOlmesartan Medoxomil

Olmesartan Medoxomil

Synonym(s):4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester;CS-866;Olmesartan medoxomil

  • CAS NO.:144689-63-4
  • Empirical Formula: C29H30N6O6
  • Molecular Weight: 558.59
  • MDL number: MFCD00944911
  • EINECS: 604-433-1
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 23:02:33
Olmesartan Medoxomil Structural

What is Olmesartan Medoxomil?

Description

Olmesartan medoxomil (Olmetec, Benicar) is an angiotensin II type 1 (AT(1)) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system, which plays a key role in the pathogenesis of hypertension. It works by blocking a substance in the body that causes the blood vessels to tighten. As a result, olmesartan relaxes the blood vessels. This lowers blood pressure and increases the supply of blood and oxygen to the heart.

Chemical properties

White to off-white crystalline powder

Originator

Sanky (Japan)

The Uses of Olmesartan Medoxomil

Olmesartan medoxomil is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems.

Definition

ChEBI: Olmesartan medoxomil is a member of biphenyls.

brand name

Benicar

General Description

Olmesartan Medoxomil is a synthetic imidazole derivative prodrug with an antihypertensive property. Upon hydrolysis, olmesartan medoxomil is converted to olmesartan. Olmesartan selectively binds to the angiotensin type 1 (AT1) receptor of angiotensin II in vascular smooth muscle and adrenal gland, thereby competing angiotensin II binding to the receptor. This prevents angiotensin II-induced vasoconstriction and decreases aldosterone production, thereby preventing aldosterone-stimulated sodium retention and potassium excretion.

Biochem/physiol Actions

Olmesartan medoxomil is a selective Angiotensin II Type I receptor blocker and antihypertensive drug. Olmesartan medoxomil is converted enzymatically to the active form olmesartan.

Clinical Use

Angiotensin-II receptor antagonist:
Hypertension

Side Effects

Dizziness or lightheadedness may occur as your body adjusts to the medication. If any of these effects persist or worsen, tell your doctor or pharmacist promptly. To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position.

Synthesis

Olmesartan Medoxomil can be synthesized in 8 steps from diaminomaleonitrile by successive reactions with trialkylorthopropanoate to access 2-propyl-imidazole-45dicarbonitrile, conversion of the two nitrile functions to the corresponding ethyl esters, followed by methylmagnesium bromide addition to give the corresponding 4-(1-hydroxyalkyl)imidazole derivative.
synthesis of Olmesartan Medoxomil
The imidazole ring of olmesartan (18) was constructed with diaminomaleonitrile 155 and trimethylorthobutyrate (156) in CH3CN then xylene to give 157 in 96% yield. Acid hydrolysis of 157 in 6N HCl gave the dicarboxylic acid intermediate. After esterification of the diacid in ethanol in the presence of HCl, diester 158 was treated with MeMgCl to give 4-(1-hydroxyalkyl) imidazole 159 in 95% yield. Alkylation of 159 with biphenyl bromide 160 in the presence of potassium tbutoxide afforded 161 in 80% yield. Ester 161 was then hydrolyzed to free carboxylic acid 162 under basic conditions, and 162 was treated with chloride 163 in the presence of K2CO3 to give ester 164 in 88% yield from 161.Lastly, the trityl group was removed with 25% aqueous acetic acid to give olmesartan (18) in 81% yield.

Drug interactions

Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: antagonism of hypotensive effect and increased risk of renal impairment with NSAIDs; hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia hypotension and renal impairment with ACE-Is and aliskiren.
Ciclosporin: increased risk of hyperkalaemia and nephrotoxicity.
Diuretics: enhanced hypotensive effect; hyperkalaemia with potassium-sparing diuretics.
ESAs: increased risk of hyperkalaemia; antagonism of hypotensive effect.
Lithium: reduced excretion (possibility of enhanced lithium toxicity).
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and nephrotoxicity.

Side Effects

The more common side effects that occur with olmesartan include:
back pain
bronchitis
diarrhea
headache
blood in your urine
high blood sugar
high triglycerides
flu-like symptoms, such as fever and body aches
sore throat, runny nose, and sinus infection

Metabolism

Olmesartan medoxomil is an ester prodrug that is hydrolysed during absorption from the gastrointestinal tract to the active form olmesartan. It is excreted in the urine and the bile as olmesartan; about 35-50% of the absorbed dose is excreted in the urine and the remainder in the bile.

Properties of Olmesartan Medoxomil

Melting point: 180°C
Boiling point: 804.2±75.0 °C(Predicted)
Density  1.38±0.1 g/cm3(Predicted)
Flash point: 180°C
storage temp.  2-8°C
solubility  DMSO: soluble20mg/mL, clear
form  powder
pka 4.15±0.10(Predicted)
color  white to beige
Decomposition  180 ºC
CAS DataBase Reference 144689-63-4(CAS DataBase Reference)

Safety information for Olmesartan Medoxomil

Signal word Warning
Pictogram(s)
ghs
Exclamation Mark
Irritant
GHS07
Precautionary Statement Codes P261:Avoid breathing dust/fume/gas/mist/vapours/spray.
P264:Wash hands thoroughly after handling.
P264:Wash skin thouroughly after handling.
P280:Wear protective gloves/protective clothing/eye protection/face protection.
P301+P312:IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

Computed Descriptors for Olmesartan Medoxomil

InChIKey UQGKUQLKSCSZGY-UHFFFAOYSA-N
SMILES C1(CCC)N(CC2=CC=C(C3=CC=CC=C3C3=NNN=N3)C=C2)C(C(OCC2=C(C)OC(=O)O2)=O)=C(C(O)(C)C)N=1

Abamectin manufacturer

Lewens Labs

1Y
Phone:91-7043057100
Whatsapp: +91 6358822736
product: Olmesartan Medoxomil 97%
Inquiry

Cefa-Cilinas Biotics Pvt Ltd

1Y
Phone:+918080701561
Whatsapp: +91 8080701561
product: 144689-63-4 Olmesartan API 99%
Inquiry

KARPSCHEM LABORATORIES PVT. LTD.

1Y
Phone:+917249203006
Whatsapp: +91 7249203006
product: Olmesartan Medoxomil (5-Methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan- 2-yl)-2-propyl-1-({4-[2-(2H-1,2,3,4-tetrazol-5- yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylate 96%
Inquiry

Varanous Labs Pvt Ltd

1Y
Phone:+917036248882
Whatsapp: +91 7036248882
product: olmesartan medoxomil 144689-63-4 98%
Inquiry

CVR Life sciences Pvt Ltd

1Y
Phone:+919912960099
Whatsapp: +91 9912960099
product: 144689-63-4 Olmesartan medoxomil API 99%
Inquiry

Chemeca Drugs Private Limited (Vegesna Laboratories Pvt Ltd)

1Y
Phone:+91-9951616502
Whatsapp: +91 9951616502
product: 144689-63-4 98%
Inquiry

Lupin Ltd

1Y
Phone:+91-8019896181
Whatsapp: +91 8019896181
product: Olmesartan medoxomil 144689-63-4 99%
Inquiry

Apotex Pharmachem India Pvt Ltd

1Y
Phone:+91-8022891000
product: Olmesartan medoxomil 98%
Inquiry

Alembic Pharmaceuticals Limited

1Y
Phone:+912652280550
product: 144689-63-4 Olmesartan medoxomil 98%
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.